Aryeh Fischer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8150492/publications.pdf

Version: 2024-02-01

84 papers 8,479 citations

38 h-index 74018 75 g-index

88 all docs 88 docs citations

88 times ranked 4944 citing authors

#	Article	IF	CITATIONS
1	Interstitial Pneumonia With Autoimmune Features. , 2022, , 298-306.		1
2	Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients. Journal of Clinical Rheumatology, 2021, 27, e482-e490.	0.5	21
3	Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease. Journal of Scleroderma and Related Disorders, 2021, 6, 11-20.	1.0	39
4	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA ₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respiratory Research, 2021, 8, e001026.	1.2	20
5	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 147-157.	5. 2	410
6	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical Rheumatology, 2019, 38, 2673-2681.	1.0	38
7	Interstitial Pneumonia with Autoimmune Features. Clinics in Chest Medicine, 2019, 40, 609-616.	0.8	5
8	Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis. American Journal of Medicine, 2019, 132, e854-e855.	0.6	1
9	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion, 2019, 35, 2015-2024.	0.9	148
10	Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung, 2019, 197, 709-713.	1.4	18
11	Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	13.9	1,025
12	Fibrosing interstitial lung diseases: knowns and unknowns. European Respiratory Review, 2019, 28, 180100.	3.0	191
13	Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States. Journal of Rheumatology, 2019, 46, 920-927.	1.0	12
14	Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis. Advances in Therapy, 2019, 36, 1100-1113.	1.3	23
15	POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes. Chest, 2019, 155, 258-260.	0.4	5
16	Rebuttal From Drs Lee and Fischer. Chest, 2019, 155, 263-264.	0.4	0
17	Interstitial Pneumonia with Autoimmune Features. Annals of the American Thoracic Society, 2019, 16, 525-533.	1.5	62
18	OP0242â€SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITI. LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS. , 2019, , .	4L	0

#	Article	IF	CITATIONS
19	OP0017â€NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPS OF PATIENTS WI'S SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM THE SENSCIS TRIAL., 2019, , .	TH	0
20	FRIO301â€GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSCIS TRIAL., 2019,,.		0
21	<p>Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention</p> . Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 283-307.	0.8	23
22	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clinic Proceedings, 2019, 94, 309-325.	1.4	78
23	Rheumatoid Arthritis–Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. Journal of Rheumatology, 2019, 46, 360-369.	1.0	130
24	Interstitial pneumonia with autoimmune features., 2019,, 140-152.		0
25	State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. European Respiratory Review, 2018, 27, 170139.	3.0	47
26	All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. Journal of Rheumatology, 2018, 45, 235-241.	1.0	29
27	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research, 2018, 5, e000289.	1.2	48
28	It takes a village to care for the patient with idiopathic pulmonary fibrosis. Cleveland Clinic Journal of Medicine, 2018, 85, 387-389.	0.6	0
29	Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respiratory Medicine, 2017, 127, 1-6.	1.3	37
30	Recent advances in connective tissue disease related interstitial lung disease. Expert Review of Respiratory Medicine, 2017, 11, 591-603.	1.0	21
31	Humanistic and cost burden of systemic sclerosis: A review of the literature. Autoimmunity Reviews, 2017, 16, 1147-1154.	2.5	39
32	Longitudinal assessment of interstitial pneumonia with autoimmune features is encouraged. Respiratory Medicine, 2017, 132, 267.	1.3	9
33	Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 475-476.	0.2	5
34	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 106-113.	0.4	7
35	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. Journal of Rheumatology, 2016, 43, 1672-1679.	1.0	222
36	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. European Respiratory Journal, 2016, 47, 1295-1296.	3.1	10

#	Article	IF	Citations
37	Characterisation of patients with interstitial pneumonia with autoimmune features. European Respiratory Journal, 2016, 47, 1767-1775.	3.1	219
38	Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respiratory Medicine, 2016, 119, 150-154.	1.3	111
39	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine, the, 2016, 4, 708-719.	5.2	754
40	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial. Respiratory Medicine, 2016, 117, 254-263.	1.3	26
41	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Review of Clinical Immunology, 2016, 12, 509-520.	1.3	16
42	Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2016, 47, 588-596.	3.1	277
43	A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia. Journal of Rheumatology, 2016, 43, 887-892.	1.0	30
44	Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease. Respiration, 2015, 90, 177-184.	1.2	38
45	Management of Connective Tissue Disease–associated Interstitial Lung Disease. Rheumatic Disease Clinics of North America, 2015, 41, 279-294.	0.8	14
46	Connective Tissue Disease–related Thoracic Disease. Clinics in Chest Medicine, 2015, 36, 283-297.	0.8	8
47	Demystifying Lung Disease in the Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2015, 41, xiii-xiv.	0.8	0
48	Primary care assessment of capillaroscopy abnormalities in patients with Raynaud's phenomenon. Clinical Rheumatology, 2015, 34, 2135-2140.	1.0	16
49	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	3.1	803
50	Connective Tissue Disease-Associated Interstitial Lung Disease. Journal of Intensive Care Medicine, 2015, 30, 392-400.	1.3	49
51	Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). Current Respiratory Medicine Reviews, 2015, 11, 175-183.	0.1	30
52	Assessment and management of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32, 2-21.	0.2	19
53	The lung may play a role in the pathogenesis of rheumatoid arthritis. International Journal of Clinical Rheumatology, 2014, 9, 295-309.	0.3	36
54	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014, 69, 436-444.	2.7	100

#	Article	IF	CITATIONS
55	Interstitial Lung Abnormalities in Rheumatoid Arthritis Are Common and Important. Chest, 2014, 146, 8-10.	0.4	7
56	Current approach to connective tissue disease-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2014, 20, 449-456.	1.2	24
57	Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 159-165.	0.8	28
58	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars in Arthritis and Rheumatism, 2014, 44, 55-62.	1.6	69
59	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 2014, 145, 454-463.	0.4	67
60	Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respiratory Medicine, 2013, 107, 1247-1252.	1.3	115
61	Recentâ€onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care and Research, 2013, 65, 314-323.	1.5	18
62	Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease. Journal of Rheumatology, 2013, 40, 640-646.	1.0	316
63	Scleroderma lung disease. European Respiratory Review, 2013, 22, 6-19.	3.0	230
64	Interstitial lung disease in connective tissue disorders. Lancet, The, 2012, 380, 689-698.	6.3	338
65	Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respiratory Medicine, 2012, 106, 1040-1047.	1.3	175
66	Connective Tissue Disease–Associated Lung Disease. Immunology and Allergy Clinics of North America, 2012, 32, 513-536.	0.7	40
67	Rheumatoid Arthritis–Interstitial Lung Disease–associated Mortality. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 372-378.	2.5	389
68	Connective Tissue Disease-Associated Interstitial Lung Disease. Chest, 2010, 138, 251-256.	0.4	275
69	Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respiratory Medicine, 2010, 104, 1350-1355.	1.3	60
70	Minor Salivary Gland Biopsy To Detect Primary Sjögren Syndrome in Patients With Interstitial Lung Disease. Chest, 2009, 136, 1072-1078.	0.4	47
71	Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2009, 136, 841-848.	0.4	90
72	Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respiratory Medicine, 2009, 103, 1719-1724.	1.3	138

#	Article	IF	CITATIONS
73	Interstitial Lung Disease. Journal of Clinical Rheumatology, 2009, 15, 95-99.	0.5	12
74	Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Clinical Pulmonary Medicine, 2009, 16, 74-80.	0.3	10
75	Clinically Significant Interstitial Lung Disease in Limited Scleroderma. Chest, 2008, 134, 601-605.	0.4	136
76	Reply to Wallis from Iseman and Fischer. Clinical Infectious Diseases, 2008, 47, 1605-1605.	2.9	0
77	Pericardial Abnormalities Predict the Presence of Echocardiographically Defined Pulmonary Arterial Hypertension in Systemic Sclerosis-Related Interstitial Lung Disease. Chest, 2007, 131, 988-992.	0.4	45
78	Response. Chest, 2007, 131, 940-941.	0.4	0
79	Unique Characteristics of Systemic Sclerosis Sine Scleroderma-Associated Interstitial Lung Disease. Chest, 2006, 130, 976-981.	0.4	90
80	Mycophenolate Mofetil Is Safe, Well Tolerated, and Preserves Lung Function in Patients With Connective Tissue Disease-Related Interstitial Lung Disease. Chest, 2006, 130, 30-36.	0.4	221
81	Update in the Diagnosis and Management of Pulmonary Vasculitis. Chest, 2006, 129, 452-465.	0.4	138
82	Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. Journal of Rheumatology, 2006, 33, 1600-5.	1.0	58
83	Radiologic vignette: Hughes-Stovin syndrome. Arthritis and Rheumatism, 2005, 53, 114-116.	6.7	15
84	P100 <break></break> Understanding the Determinants of Health-Related Quality of Life in Rheumatoid Arthritis-Associated Interstitial Lung Disease. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	0